DTX-021
Glabellar Lines, Periorbital Rhytids (Aesthetic); Chronic Migraine, Blepharospasm, Spasticity, Overactive Bladder (Therapeutic)
Phase 3Active
Key Facts
Indication
Glabellar Lines, Periorbital Rhytids (Aesthetic); Chronic Migraine, Blepharospasm, Spasticity, Overactive Bladder (Therapeutic)
Phase
Phase 3
Status
Active
Company
About Aquavit Pharmaceuticals
Aquavit Pharmaceuticals is a clinical-stage biotech company pioneering personalized healthcare via advanced delivery platforms. Its core assets include DTX-021, a botulinum toxin in development for aesthetic and therapeutic indications, and the commercial AQUAGOLD® microchannel delivery device. The company leverages a network of high-profile clinical investigators and is progressing DTX-021 through the FDA regulatory pathway, with recent IND clearances marking a key transition into clinical trials. Its strategy targets the large and growing neuromodulator and precision dermatology markets.
View full company profile